Clinical trial
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene…
NCT02355574 · Castle Biosciences Incorporated, Industry · Terminated
Key facts
| NCT number | NCT02355574 |
|---|---|
| Title | 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results |
| Official title | An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics |
| Acronym | INTEGRATE |
| Lead sponsor | Castle Biosciences Incorporated, Industry |
| Status | Terminated |
| Study type | Observational [Patient Registry] |
| Conditions | Cutaneous Melanoma |
| Enrollment | 301 |
| Start date | Jun 1, 2014 |
| Primary completion | Feb 1, 2021 |
| Completion | Jul 1, 2021 |
| First posted | Feb 4, 2015 |
| Last update posted | Oct 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: